Bress Lab

Research focus

NIH R01 · 2025

Examining Effects of Intensive BP Control on MCI/Dementia and Plasma Biomarker Trajectories by AD Pathology: Elucidating neuroprotective effects in the racially and ethnically diverse SPRINT trial

ABSTRACT: Alzheimer’s disease (AD) and AD-related dementias (AD/ADRD) are leading causes of dependence and disability in older adults, projected to impact ~153 million people worldwide by 2050. Hypertension (HTN) increases the risk of both AD and Vascular Cognitive Impairment and Dementia (VCID). Black and Hispanic adults have higher average blood pressure (BP) and nearly 1.5 to 2 times higher dementia incidence than white adults, despite having less brain β-amyloid (Aβ). The Systolic Blood Pressure Intervention Trial (SPRINT), which included 9,361 US adults, found that intensive vs standard systolic BP (SBP) treatment (<120 vs <140 mm Hg) reduced risk of combined emergent mild cognitive…

From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.